Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Capital Expenditures (2020 - 2026)

Bioventus filings provide 6 years of Capital Expenditures readings, the most recent being -$1.7 million for Q4 2025.

  • On a quarterly basis, Capital Expenditures fell 295.07% to -$1.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $240000.0, a 76.14% decrease, with the full-year FY2025 number at $240000.0, down 76.14% from a year prior.
  • Capital Expenditures hit -$1.7 million in Q4 2025 for Bioventus, down from $473000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $6.0 million in Q3 2023 to a low of -$5.7 million in Q4 2023.
  • Median Capital Expenditures over the past 5 years was $224000.0 (2021), compared with a mean of $183550.0.
  • The widest YoY moves for Capital Expenditures: up 4584.21% in 2023, down 28700.0% in 2023.
  • Bioventus' Capital Expenditures stood at -$3.9 million in 2021, then surged by 78.03% to -$851000.0 in 2022, then plummeted by 567.69% to -$5.7 million in 2023, then surged by 115.72% to $893000.0 in 2024, then plummeted by 295.07% to -$1.7 million in 2025.
  • The last three reported values for Capital Expenditures were -$1.7 million (Q4 2025), $473000.0 (Q3 2025), and $683000.0 (Q2 2025) per Business Quant data.